You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Identification of annexin a4 as cisplatin-susceptibility related protein in malignant mesothelioma
- In: Posters C - Drug Design and Discovery
- At: PSWC, Melbourne (Australia) (2014)
- Type: Poster
- Poster code: PC-017
- By: NAGANO, Kazuya (National Institute of Biomedical Innovation, Laboratory of Biopharmaceutical Research, Osaka, Japan)
- Co-author(s): Yamashita, Takuya (National Institute of Biomedical Innovation, Osaka, Japan)
Inoue, Masaki (National Institute of Biomedical Innovation, Osaka, Japan)
Higashisaka, Kazuma (Osaka University, Osaka, Japan)
Yoshioka, Yasuo (Osaka University, Osaka, Japan)
Abe, Yasuhiro (National Institute of Biomedical Innovation, Osaka, Japan)
Mukai, Yohei (National Institute of Biomedical Innovation, Osaka, Japan)
Kamada, Haruhiko (National Institute of Biomedical Innovation, Osaka, Japan)
Tsutsumi, Yasuo (Osaka University, Osaka, Japan)
Tsunoda, Shin-Ichi (National Institute of Biomedical Innovation, Osaka, Japan) - Abstract:
Introduction
Cisplatin (CDDP) is a highly effective drug for malignant mesothelioma. However, its response rate is only 20%. For this reason, it is important to elucidate the molecular mechanism of CDDP- susceptibility and to distinguish responders from non-responders. Here, in order to identify proteins related to CDDP-susceptibility, we.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026